Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer

Immunity. 2023 Nov 14;56(11):2602-2620.e10. doi: 10.1016/j.immuni.2023.10.009.

Abstract

Human cytomegalovirus (HCMV) can cause severe diseases in fetuses, newborns, and immunocompromised individuals. Currently, no vaccines are approved, and treatment options are limited. Here, we analyzed the human B cell response of four HCMV top neutralizers from a cohort of 9,000 individuals. By single-cell analyses of memory B cells targeting the pentameric and trimeric HCMV surface complexes, we identified vulnerable sites on the shared gH/gL subunits as well as complex-specific subunits UL128/130/131A and gO. Using high-resolution cryogenic electron microscopy, we revealed the structural basis of the neutralization mechanisms of antibodies targeting various binding sites. Moreover, we identified highly potent antibodies that neutralized a broad spectrum of HCMV strains, including primary clinical isolates, that outperform known antibodies used in clinical trials. Our study provides a deep understanding of the mechanisms of HCMV neutralization and identifies promising antibody candidates to prevent and treat HCMV infection.

Keywords: HCMV; Pentamer; Trimer; antiviral therapy; broadly neutralizing antibody; cryogenic electron microscopy; epitope map; neutralizaton mechanisms; single B cell.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Cytomegalovirus*
  • Humans
  • Infant, Newborn
  • Membrane Glycoproteins
  • Memory B Cells
  • Single-Cell Analysis
  • Viral Envelope Proteins*

Substances

  • Viral Envelope Proteins
  • Membrane Glycoproteins
  • Antibodies, Neutralizing
  • Antibodies, Viral